Insights

Gathering insights about Capital…

Similar companies to Capital

Capital Tech Stack

Capital uses 8 technology products and services including Vercel Analytics, MySQL, Google Workspace, and more. Explore Capital's tech stack below.

Vercel Analytics
Analytics
MySQL
Database
Google Workspace
Email
Svelte
Javascript Frameworks
Python
Programming Languages
Kotlin
Programming Languages
Google
Search Engines
SvelteKit
UI Frameworks

Media & News

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern In HS, over 4 weeks of therapy, InflaRx observed rapid and clinically meaningful reductions in abscesses and nodules (ANs) and draining tunnels (dTs), robust HiSCR responses that continued to deepen four weeks after the treatment period, with substantial reductions in patient reported pain scores, overall demonstrating the potential for biologic-like efficacy In CSU, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients, and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7) With a priority of enabling Phase 2b development for INF904 in HS, InflaRx continues ongoing clinical trial preparation towards its goal of Phase 2b initiation in 2026 Given INF904's potential as a pipeline-in-a-product and increased industry interest in the C5aR mechanism of action, InflaRx continues to foster active dialog with potential collaborators in an effort to expedite the Company's total development goals with INF904, and to also drive development in CSU and additional inflammatory disorders InflaRx will host a webcast to discuss the topline data today at 8:00 AM EST / 2:00 PM CET JENA, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced positive topline data from a Phase 2a basket study exploring INF904 in HS and CSU.
Nov 10, 2025 | www.globenewswire.com
Steady Hands In Shifting Skies: Why CSU Remains A Long-Term Star
Constellation Software presents a compelling long-term investment opportunity after a 25% stock price decline driven by AI concerns and leadership transition. CSU's decentralized structure, focus on mission-critical verticals, and disciplined capital allocation provide resilience against AI disruption and key-person risk. The transition to Mark Miller as CEO ensures continuity, while insider buying and a historically attractive valuation signal management's confidence in CSU's prospects.
Oct 24, 2025 | seekingalpha.com
Constellation Software Inc. Announces Release Date for Third Quarter Results
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its third quarter results on November 7, 2025.
Oct 20, 2025 | www.globenewswire.com
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025. RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
Oct 19, 2025 | www.globenewswire.com
Nuvini Provides FY2025 EBITDA Guidance and Business Outlook
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer and operator of vertical market SaaS businesses in Latin America, today provided its fiscal year 2025 and outlined key drivers of its growth strategy. For the twelve months ending December 31, 2025, Nuvini expects to generate approximately R$50 to R$60 million of EBITDA, excluding the impact of acquisitions.
Oct 16, 2025 | www.globenewswire.com
Constellation Software Inc. - Special Call
Constellation Software Inc. - Special Call Company Participants Jamal Baksh - CFO & Director Mark Miller - President & COO Conference Call Participants Richard Tse - National Bank Financial, Inc., Research Division Thanos Moschopoulos - BMO Capital Markets Equity Research David Kwan - TD Cowen, Research Division Samad Samana - Jefferies LLC, Research Division Paul Treiber - RBC Capital Markets, Research Division Kevin McVeigh - UBS Investment Bank, Research Division Presentation Operator Good afternoon, and welcome to the Constellation Software Inc. Conference Call and Webcast. [Operator Instructions] Please note this event is being recorded.
Oct 01, 2025 | seekingalpha.com
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines 2,3 Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology portfolio EAST HANOVER, N.J. , Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.
Sep 30, 2025 | www.prnewswire.com

Capital's Email Address Formats

Capital uses at least 1 format(s):

Capital Email Formats	Example	Percentage

Frequently Asked Questions

Where is Capital's headquarters located?

Capital's main headquarters is located at Fully Remote, US. The company has employees across 1 continents, including North America.

What is Capital's stock symbol?

Capital is a publicly traded company; the company's stock symbol is CSU.

What is Capital's official website and social media links?

Capital's official website is capital.xyz and has social profiles on LinkedIn Crunchbase.

What is Capital's NAICS code?

Capital's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Capital have currently?

As of September 2025, Capital has approximately 11 employees across 1 continents, including North America. Key team members include Chief Executive Officer: S. B.Co-Founder: S. C.. Explore Capital's employee directory with LeadIQ.

What industry does Capital belong to?

Capital operates in the Technology, Information and Internet industry.

What technology does Capital use?

Capital's tech stack includes Vercel AnalyticsMySQLGoogle WorkspaceSveltePythonKotlinGoogleSvelteKit.

Capital

Q: What is Capital's official website and social media links?

Capital's official website is capital.xyz. Capital has social profiles on LinkedIn.

Q: How many employees does Capital have currently?

Capital has approximately 11 employees.

Q: What technology does Capital use?

Capital's tech stack includes Svelte, GraphQL, GitHub, iOS, Google Tag Manager.

Technology, Information and InternetFully Remote, United States11-50 Employees

Capital provides software that enables founders to raise, hold, spend, and send funds all in one place. Capital has evolved its flagship fundraising tool (formerly known as Party Round) to provide founders with banking solutions that streamline their startups.